AR
ARVN.US Arvinas Inc
- Market cap
- USD 447M
- P/E
- -
- P/B
- 0.87x
- ROE
- 15.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARVN.US undervalued?
Graham numberThe Graham number of Arvinas Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arvinas Inc fundamental analysis
No fundamental analysis for Arvinas Inc yet.
Arvinas Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase …
Full company profileArvinas Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arvinas Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.67M | 7.58M | 14.3M | 43.0M | 21.8M | 46.7M | 131M | 78.5M | 263M | 263M | 354M |
| Gross Profit | 6.67M | 7.58M | 14.3M | 43.0M | 21.8M | 46.7M | 131M | 78.5M | 263M | 257M | 341M |
| Operating Income | -16.5M | -24.8M | -43.8M | -51.5M | -125M | -195M | -263M | -402M | -250M | -115M | 56.4M |
| EBITDA | -13.9M | -23.7M | -43.1M | -49.3M | -121M | -189M | -255M | -360M | -192M | -75.3M | 59.1M |
| Net Income | -14.4M | -24.0M | -41.5M | -62.1M | -112M | -183M | -272M | -367M | -199M | -80.8M | 77.2M |
| EPS | -0.80 | -1.16 | -1.31 | -1.89 | -2.83 | -3.66 | -5.11 | -6.62 | -2.77 | -1.24 | 1.18 |
| Balance Sheet | |||||||||||
| Total Assets | 37.9M | 66.8M | 199M | 302M | 717M | 1.58B | 1.27B | 1.30B | 1.09B | 718M | 608M |
| Total Liabilities | 13.9M | 66.6M | 62.6M | 75.0M | 75.2M | 800M | 704M | 645M | 530M | 284M | 93.7M |
| Shareholders' Equity | 24.0M | 246K | 137M | 227M | 642M | 782M | 565M | 660M | 562M | 434M | 514M |
| Cash & Short-term Investments | 35.6M | 39.2M | 188M | 281M | 689M | 1.50B | 1.21B | 1.26B | 1.04B | 685M | 558M |
| Total Debt | 454K | 310K | 2.15M | 4.39M | 4.10M | 5.00M | 5.50M | 3.20M | 9.70M | 8.90M | 7.60M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.4M | 5.11M | -16.1M | -40.6M | -89.8M | 559M | -274M | -348M | -259M | -274M | -171M |
| Capital Expenditure | 307K | 1.01M | 2.83M | 6.24M | 6.45M | 4.70M | 6.80M | 2.90M | 1.80M | 1.90M | 2.27M |
| Free Cash Flow | -19.7M | 4.10M | -18.9M | -46.9M | -96.2M | 555M | -280M | -351M | -261M | -276M | -172M |
| Ratios | |||||||||||
| ROE | -59.7% | -9,781.3% | -30.4% | -27.4% | -17.4% | -23.4% | -48.1% | -55.7% | -35.4% | -18.6% | 15.0% |
| ROA | -37.8% | -36.0% | -20.8% | -20.6% | -15.6% | -11.6% | -21.4% | -28.2% | -18.2% | -11.3% | 12.7% |
| Net Profit Margin | -215.2% | -317.3% | -289.6% | -144.6% | -512.7% | -392.3% | -206.9% | -467.9% | -75.5% | -30.8% | 21.8% |
| Debt to Equity | 0.02x | 1.26x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arvinas Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 3.42M | 0.10 | - |
| 2018 | USD 60.5M | 1.91 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Arvinas Inc
- Insiders 7.79%
- Institutions 87.06%
- Public & others 5.15%
- Shares outstanding 65.5M
- Free float 56.9M
Top funds holding ARVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.92M | 2.93% | 0.00% | Sep 2026 |
| Vanguard Strategic Equity Inv | 1.71M | 2.61% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.52M | 2.32% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 896K | 1.37% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 653K | 1.00% | +0.68% | Aug 2026 |
| BlackRock Advantage Small Cap Core Instl | 647K | 0.99% | +8.21% | Sep 2026 |
| Bridge Builder Small Cap Fund | 578K | 0.88% | +69.47% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 572K | 0.87% | +10.51% | Sep 2026 |
| Federated Hermes MDT Small Cap Core IS | 561K | 0.86% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 489K | 0.75% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 479K | 0.73% | +0.27% | Oct 2026 |
| iShares Biotechnology ETF | 456K | 0.70% | -0.19% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 451K | 0.69% | +2.88% | Oct 2026 |
| Vanguard Russell 2000 ETF | 345K | 0.53% | +1.12% | Sep 2026 |
| Selectra J. Lamarck Biotech A | 320K | 0.49% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 314K | 0.48% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 296K | 0.45% | +126.14% | Sep 2026 |
| Federated Hermes MDT Small Cap Growth IS | 256K | 0.39% | 0.00% | Sep 2026 |
| Nordea 2 - BetaPlus Enh GlSCap Eq BI USD | 250K | 0.38% | -9.48% | Sep 2026 |
| Vanguard Market Neutral I | 244K | 0.37% | 0.00% | Jun 2026 |
Top institutions holding ARVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 7.61M | 11.62% | +11.94% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.12M | 6.30% | +6.01% | Jun 2026 |
| D. E. Shaw & Co LP | 3.50M | 5.34% | -3.94% | Jun 2026 |
| Pfizer Inc | 3.46M | 5.28% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 2.80M | 4.27% | +41.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.71M | 4.14% | +0.92% | Jun 2026 |
| Two Sigma Investments LLC | 2.57M | 3.93% | +40.46% | Jun 2026 |
| State Street Corp | 2.20M | 3.35% | +20.15% | Jun 2026 |
| Geode Capital Management, LLC | 1.67M | 2.55% | +7.07% | Jun 2026 |
| Qube Research & Technologies | 1.59M | 2.43% | +32.51% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.41M | 2.16% | -2.00% | Jun 2026 |
| Federated Hermes Inc | 1.36M | 2.07% | +18.88% | Jun 2026 |
| Nextech Invest, Ltd. | 1.12M | 1.71% | +108.14% | Jun 2026 |
| Fort Hoosac Management, LLC | 884K | 1.35% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 848K | 1.30% | -10.68% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 811K | 1.24% | +23.90% | Sep 2026 |
| Hillsdale Investment Management Inc. | 751K | 1.15% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 728K | 1.11% | +70.49% | Jun 2026 |
| TCG Crossover Management, LLC | 707K | 1.08% | -70.38% | Jun 2026 |
| The Goldman Sachs Group Inc | 641K | 0.98% | -15.33% | Jun 2026 |
Arvinas Inc company profile
- Company name
- Arvinas Inc
- Ticker
- ARVN.US
- Exchange
- USA Stocks
- Listed since
- Sep 27, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 246
- Fiscal year end
- December
- Address
- 5 Science Park, New Haven, CT, United States, 06511
- Phone
- 203 535 1456
- Website
- arvinas.com
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas Inc management
8- Mr. Andrew R. SaikCFO & Treasurer · born 1969
- Ms. Angela M. Cacace Ph.D.Chief Scientific Officer · born 1968
- Dr. Randy Teel Ph.D.CEO, President & Director · born 1980
- Mr. David K. Loomis M.B.A.VP & Chief Accounting Officer · born 1974
- Mr. Jeff BoyleVice President of Investor Relations
- Mr. Jared M. Freedberg J.D.General Counsel & Corporate Secretary · born 1969
- Mr. Steve WeissSenior VP & Chief Human Resources Officer · born 1970
- Ms. Kelly PageSenior VP & Global Head of Oncology Strategy and Program Leadership